vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and LCNB CORP (LCNB). Click either name above to swap in a different company.
LCNB CORP is the larger business by last-quarter revenue ($23.9M vs $21.9M, roughly 1.1× Cue Biopharma, Inc.). LCNB CORP runs the higher net margin — 23.7% vs 7.2%, a 16.5% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 5.1%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 15.7%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
LCNB Corp is a United States-based financial holding company that operates through its national bank subsidiary, providing a full suite of retail and commercial banking products and services including deposit accounts, various loan products, wealth management, and insurance solutions primarily to individual consumers, small and medium-sized enterprises and local community organizations across regional markets in Ohio.
CUE vs LCNB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $23.9M |
| Net Profit | $1.6M | $5.7M |
| Gross Margin | — | — |
| Operating Margin | 9.0% | 29.2% |
| Net Margin | 7.2% | 23.7% |
| Revenue YoY | 1292.3% | 5.1% |
| Net Profit YoY | 116.7% | -7.6% |
| EPS (diluted) | $0.05 | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | $23.9M | ||
| Q3 25 | $2.1M | $23.8M | ||
| Q2 25 | $3.0M | $22.8M | ||
| Q1 25 | $421.0K | $21.5M | ||
| Q4 24 | $1.6M | $22.7M | ||
| Q3 24 | $3.3M | $21.4M | ||
| Q2 24 | $2.7M | $19.3M | ||
| Q1 24 | $1.7M | $17.8M |
| Q4 25 | $1.6M | $5.7M | ||
| Q3 25 | $-7.4M | $6.9M | ||
| Q2 25 | $-8.5M | $5.9M | ||
| Q1 25 | $-12.3M | $4.6M | ||
| Q4 24 | — | $6.1M | ||
| Q3 24 | $-8.7M | $4.5M | ||
| Q2 24 | $-10.2M | $925.0K | ||
| Q1 24 | $-12.3M | $1.9M |
| Q4 25 | 9.0% | 29.2% | ||
| Q3 25 | -353.4% | 35.6% | ||
| Q2 25 | -292.3% | 31.6% | ||
| Q1 25 | -2921.4% | 25.6% | ||
| Q4 24 | — | 32.9% | ||
| Q3 24 | -264.2% | 24.9% | ||
| Q2 24 | -390.6% | 4.9% | ||
| Q1 24 | -737.8% | 12.5% |
| Q4 25 | 7.2% | 23.7% | ||
| Q3 25 | -346.6% | 29.1% | ||
| Q2 25 | -287.1% | 26.0% | ||
| Q1 25 | -2911.4% | 21.4% | ||
| Q4 24 | — | 27.0% | ||
| Q3 24 | -259.6% | 21.2% | ||
| Q2 24 | -382.7% | 4.8% | ||
| Q1 24 | -719.1% | 10.7% |
| Q4 25 | $0.05 | $0.40 | ||
| Q3 25 | $-0.07 | $0.49 | ||
| Q2 25 | $-0.09 | $0.41 | ||
| Q1 25 | $-0.17 | $0.33 | ||
| Q4 24 | — | $0.44 | ||
| Q3 24 | $-0.17 | $0.31 | ||
| Q2 24 | $-0.20 | $0.07 | ||
| Q1 24 | $-0.25 | $0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | $21.6M |
| Total DebtLower is stronger | — | $104.4M |
| Stockholders' EquityBook value | $26.4M | $273.9M |
| Total Assets | $42.2M | $2.2B |
| Debt / EquityLower = less leverage | — | 0.38× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | $21.6M | ||
| Q3 25 | $11.7M | $35.9M | ||
| Q2 25 | $27.5M | $49.8M | ||
| Q1 25 | $13.1M | $37.7M | ||
| Q4 24 | $22.5M | $35.7M | ||
| Q3 24 | $32.4M | $39.4M | ||
| Q2 24 | $30.0M | $34.9M | ||
| Q1 24 | $41.0M | $33.0M |
| Q4 25 | — | $104.4M | ||
| Q3 25 | — | $104.7M | ||
| Q2 25 | — | $105.0M | ||
| Q1 25 | — | $104.6M | ||
| Q4 24 | — | $155.2M | ||
| Q3 24 | $1.0M | $155.7M | ||
| Q2 24 | $2.0M | $162.2M | ||
| Q1 24 | $3.0M | $162.6M |
| Q4 25 | $26.4M | $273.9M | ||
| Q3 25 | $13.2M | $269.9M | ||
| Q2 25 | $18.2M | $263.5M | ||
| Q1 25 | $6.6M | $258.7M | ||
| Q4 24 | $17.5M | $253.0M | ||
| Q3 24 | $25.4M | $253.2M | ||
| Q2 24 | $21.6M | $245.2M | ||
| Q1 24 | $30.0M | $233.7M |
| Q4 25 | $42.2M | $2.2B | ||
| Q3 25 | $31.6M | $2.2B | ||
| Q2 25 | $40.7M | $2.3B | ||
| Q1 25 | $22.3M | $2.3B | ||
| Q4 24 | $32.2M | $2.3B | ||
| Q3 24 | $44.8M | $2.3B | ||
| Q2 24 | $42.3M | $2.4B | ||
| Q1 24 | $54.0M | $2.3B |
| Q4 25 | — | 0.38× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.40× | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | 0.04× | 0.61× | ||
| Q2 24 | 0.09× | 0.66× | ||
| Q1 24 | 0.10× | 0.70× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $34.4M |
| Free Cash FlowOCF − Capex | — | $33.4M |
| FCF MarginFCF / Revenue | — | 140.2% |
| Capex IntensityCapex / Revenue | 0.0% | 4.0% |
| Cash ConversionOCF / Net Profit | -0.68× | 6.08× |
| TTM Free Cash FlowTrailing 4 quarters | — | $54.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $34.4M | ||
| Q3 25 | $-9.0M | $14.0M | ||
| Q2 25 | $-3.4M | $5.5M | ||
| Q1 25 | $-8.2M | $2.2M | ||
| Q4 24 | $-36.3M | $93.2M | ||
| Q3 24 | $-7.5M | $11.9M | ||
| Q2 24 | $-10.0M | $54.9M | ||
| Q1 24 | $-9.8M | $-11.9M |
| Q4 25 | — | $33.4M | ||
| Q3 25 | — | $13.7M | ||
| Q2 25 | $-3.4M | $5.2M | ||
| Q1 25 | $-8.3M | $2.1M | ||
| Q4 24 | $-36.4M | $89.4M | ||
| Q3 24 | $-7.5M | $10.5M | ||
| Q2 24 | $-10.0M | $53.8M | ||
| Q1 24 | $-9.8M | $-12.8M |
| Q4 25 | — | 140.2% | ||
| Q3 25 | — | 57.4% | ||
| Q2 25 | -116.5% | 23.0% | ||
| Q1 25 | -1976.7% | 10.0% | ||
| Q4 24 | -2309.3% | 394.0% | ||
| Q3 24 | -225.7% | 49.0% | ||
| Q2 24 | -376.2% | 278.6% | ||
| Q1 24 | -573.0% | -71.8% |
| Q4 25 | 0.0% | 4.0% | ||
| Q3 25 | 0.0% | 1.3% | ||
| Q2 25 | 0.9% | 1.0% | ||
| Q1 25 | 35.6% | 0.3% | ||
| Q4 24 | 4.2% | 16.7% | ||
| Q3 24 | 0.0% | 6.7% | ||
| Q2 24 | 0.4% | 5.9% | ||
| Q1 24 | 3.2% | 4.8% |
| Q4 25 | -0.68× | 6.08× | ||
| Q3 25 | — | 2.02× | ||
| Q2 25 | — | 0.92× | ||
| Q1 25 | — | 0.48× | ||
| Q4 24 | — | 15.23× | ||
| Q3 24 | — | 2.63× | ||
| Q2 24 | — | 59.35× | ||
| Q1 24 | — | -6.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
LCNB
Segment breakdown not available.
